Chlorthalidone more effective than HCTZ in reducing MACE in long term: Study
Written By : Dr. Nandita Mohan
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2021-01-24 16:00 GMT | Update On 2021-01-25 07:29 GMT
According to recent research, investigators from the NYU School of Medicine, New York City, New York, USA found out that over the short-term there were no differences in the net clinical benefit between hydrochlorothiazide and chlorthalidone.The study is published in the Journal of Hypertension.There is continuous debate whether chlorthalidone (CTD) and hydrochlorothiazide (HCTZ) differ...
Login or Register to read the full article
According to recent research, investigators from the NYU School of Medicine, New York City, New York, USA found out that over the short-term there were no differences in the net clinical benefit between hydrochlorothiazide and chlorthalidone.
The study is published in the Journal of Hypertension.
There is continuous debate whether chlorthalidone (CTD) and hydrochlorothiazide (HCTZ) differ in reducing major cardiovascular events (MACE). HCTZ is prescribed 10 times more commonly than CTD.
Hence, Roush, George C. and colleagues conducted this study to assess the difference between Chlorthalidone and hydrochlorothiazide in terms of major cardiovascular events, blood pressure, left ventricular mass, and adverse effects.
They carried out a systematic literature search which yielded 14 references, including two network meta-analyses of randomized trials with MACE and left ventricular mass as outcomes.
The findings were-
a. The network meta-analysis of randomized trials showed CTD reducing MACE more than HCTZ, hazard ratio = 0.79 (0.72–0.88), P < 0.0001, and an observational cohort study gave an identical point estimate: hazard ratio = 0.79 (0.68–0.92), P = 0.002.
b. In contrast, two observational cohort studies reported no differences between CTD and HCTZ.
c. However, in the studies showing the superiority of CTD median follow-up was 4.3 and 7.0 years, respectively, whereas in the latter studies showing no difference between the two drugs follow-up was only 0.95 and 0.25 years.
d. As differences in outcomes for MACE in hypertension trials with various interventions only emerge after prolonged (>1 year) therapy, differences in follow-up explain these discrepant results.
e. CTD also more effectively reduced left ventricular mass in observational data and network analysis of trials.
f. These advantages of CTD over HCTZ are consistent with greater reductions in night-time blood pressure, greater reductions in oxidative stress and platelet aggregation, and greater improvements in endothelial function.
Therefore, they concluded that "Over the short-term there were no differences in the net clinical benefit between HCTZ and CTD. However, long-term available data document CTD to be significantly more effective in reducing MACE than HCTZ."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd